Bradley Foster & Sargent Inc. CT grew its position in Eli Lilly And Co (NYSE:LLY) by 0.5% during the first quarter, Holdings Channel reports. The fund owned 33,130 shares of the company’s stock after acquiring an additional 172 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Eli Lilly And Co were worth $4,299,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. First Interstate Bank increased its position in shares of Eli Lilly And Co by 35.2% during the 1st quarter. First Interstate Bank now owns 1,781 shares of the company’s stock valued at $231,000 after purchasing an additional 464 shares during the last quarter. German American Bancorp Inc. bought a new position in Eli Lilly And Co in the 1st quarter valued at $221,000. Pinnacle Financial Partners Inc. grew its position in Eli Lilly And Co by 4.8% in the 1st quarter. Pinnacle Financial Partners Inc. now owns 48,618 shares of the company’s stock valued at $6,308,000 after acquiring an additional 2,239 shares during the last quarter. Telemus Capital LLC grew its position in Eli Lilly And Co by 29.1% in the 1st quarter. Telemus Capital LLC now owns 8,466 shares of the company’s stock valued at $1,099,000 after acquiring an additional 1,909 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its position in Eli Lilly And Co by 22.5% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 181,004 shares of the company’s stock valued at $23,488,000 after acquiring an additional 33,302 shares during the last quarter. 84.49% of the stock is currently owned by institutional investors and hedge funds.
Shares of LLY stock opened at $116.23 on Tuesday. Eli Lilly And Co has a twelve month low of $81.61 and a twelve month high of $132.13. The firm has a market capitalization of $112.63 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 2.06 and a beta of 0.27. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Friday, May 17th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.22%. The ex-dividend date of this dividend is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is 46.49%.
LLY has been the topic of several research analyst reports. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. initiated coverage on Eli Lilly And Co in a research report on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price objective on the stock. Guggenheim downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price objective on the stock. in a research report on Thursday, April 11th. UBS Group initiated coverage on Eli Lilly And Co in a research report on Wednesday, January 23rd. They issued a “buy” rating and a $131.00 price objective on the stock. Finally, Credit Suisse Group set a $121.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a research report on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Eli Lilly And Co has a consensus rating of “Buy” and a consensus price target of $118.15.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $124.19, for a total value of $24,217,050.00. Following the completion of the sale, the insider now directly owns 117,425,304 shares in the company, valued at $14,583,048,503.76. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Insiders sold a total of 640,959 shares of company stock valued at $81,539,352 over the last quarter. Company insiders own 0.11% of the company’s stock.
WARNING: This news story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/21/bradley-foster-sargent-inc-ct-grows-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Short Selling – Explanation For Shorting Stocks
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.